Futamura-Takahashi Junko, Tanaka Taisaku, Sugawara Hajime, Iwashita Shinzo, Imajo Seiichi, Oyama Yoshiaki, Muto Tsuyoshi
Asubio Pharma Co., Ltd, 6-4-3 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan.
Asubio Pharma Co., Ltd, 6-4-3 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan.
Bioorg Med Chem Lett. 2018 Jan 15;28(2):188-192. doi: 10.1016/j.bmcl.2017.11.031. Epub 2017 Nov 16.
Based on insight from the X-ray crystal structure of human chymase in complex with compound 1, a lactam carbonyl of the diazepane core was exchanged with O-substituted oxyimino group, leading to amidoxime derivatives. This modification resulted in highly potent chymase inhibitors, such as O-phenylamidoxime 5f. X-ray crystal structure analysis indicated that compound 5f induced movement of the Leu99 and Tyr94 side chains at the S2 site, and the increase in inhibitory activity of O-phenyl amidoxime derivatives suggested that the O-phenyl moiety interacted with the Tyr94 residue. Surface plasmon resonance experiments showed that compound 5f had slower association and dissociation kinetics and the calculated residence time of compound 5f to human chymase was extended compared to that of amide compound 1.
基于人糜蛋白酶与化合物1复合物的X射线晶体结构的见解,将二氮杂环庚烷核心的内酰胺羰基与O-取代的氧亚氨基基团交换,得到偕胺肟衍生物。这种修饰产生了高效的糜蛋白酶抑制剂,如O-苯基偕胺肟5f。X射线晶体结构分析表明,化合物5f诱导了S2位点的Leu99和Tyr94侧链的移动,并且O-苯基偕胺肟衍生物抑制活性的增加表明O-苯基部分与Tyr94残基相互作用。表面等离子体共振实验表明,化合物5f的结合和解离动力学较慢,并且与酰胺化合物1相比,化合物5f与人糜蛋白酶的计算停留时间延长。